Modular Medical Inc is a medical technology company focused on developing innovative solutions for diabetes management, particularly through its advanced insulin delivery systems. The company aims to enhance the quality of life for individuals living with diabetes by creating user-friendly, reliable, and effective devices that streamline the insulin administration process. By harnessing cutting-edge technology, Modular Medical seeks to empower patients and healthcare providers with improved tools for better diabetes control and overall health outcomes.
SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (Nasdaq:MODD), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced it will hold a conference call and webcast on Thursday, December 5, 2024, at 10:00 a.m. Eastern Time to provide a business update.
Modular Medical (NASDAQ: MODD) is an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult “almost-pumpers” with its user-friendly and affordable design. The company recently announced its pricing of an underwritten public offering of 5,450,573 shares of its common stock. The offering was led by existing institutional investors, including the company’s largest shareholder, Manchester Explorer, L.P., and is managed by Jeb Besser, Modular Medical’s CEO. Gross proceeds to the company are expected at approximately $8.2 million, with shares of common stock each being sold at a price to the public of $1.50. Titan Partners Group, a division of American Capital Partners, is acting as sole bookrunner for the offering.
SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that it has priced an underwritten public offering (the "offering") of 5,450,573 shares of its common stock. The offering was led by existing institutional investors, including Manchester Explorer, L.P., which is the largest shareholder of the Company and is managed by Jeb Besser, Modular Medical's Chief Executive Officer. The shares of common stock are being sold at a price to the public of $1.50 per share of common stock, less underwriting discounts and commissions.
SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that it has commenced an underwritten public offering (the "offering") of shares of its common stock (or pre-funded warrants to purchase shares of its common stock in lieu thereof). Modular Medical also has granted the underwriter a 30-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock (or pre-funded warrants) sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All shares of common stock and pre-funded warrants to be sold in the proposed offering will be sold by Modular Medical.
SAN DIEGO, CA / ACCESSWIRE / November 11, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that it is a Gold sponsor of the upcoming, first annual Achieving Diabetes Equity in Practice Today (ADEPT) Conference taking place at the Chicago Marriott Downtown on November 12 and 13,2024. The ADEPT Conference, which is the result of a collaborative effort between the American Diabetes Association and the T1D Exchange, will bring together key stakeholders focused on achieving health equity in type 1 and type 2 diabetes.
In a wave of groundbreaking developments, Cardiol Therapeutics Inc. (Nasdaq: CRDL), Modular Medical, Inc. (Nasdaq: MODD), and Cyngn Inc. (Nasdaq: CYN) each report advancements that promise to reshape the pharmaceutical, medical, and industrial automation landscapes.
Investors in healthcare and biotech sectors should keep an eye on several prominent companies making strides in innovation, clinical trials, and global expansion. Modular Medical (NASDAQ: MODD), Cardiol Therapeutics (NASDAQ: CRDL) , DBV Technologies (NASDAQ: DBVT) , and Virax Biolabs (NASDAQ: VRAX) are key players to watch in the ever-evolving medical landscape. Each company has announced significant developments in technology, trials, and product distribution, solidifying their positions in the market.
SAN DIEGO, CA / ACCESSWIRE / September 30, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its user-friendly and affordable design, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on October 1, 2024.
Modular Medical shares are trading higher Thursday after the company announced it has received U. S. Food and Drug Administration (FDA) clearance to market and sell its MODD1 pump in the United States.
Here are five companies in the spotlight, under $5 across technology, biomedical, healthcare, aerospace, commercial real estate and medical sectors, demonstrating strong market trends, volume, and awareness:
SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it will hold a conference call and webcast tomorrow, Thursday, September 5, 2024, at 8:30 a.m. Eastern Time to discuss the U. S. Food and Drug Administration ("FDA") clearance of its MODD1 pump, as well as next steps and milestones.
SAN DIEGO, CA / ACCESSWIRE / August 7, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch the next generation of easy-to-use, prescribe and live with affordable insulin pump technology, today announced it has begun the transfer of its pilot line manufacturing operations to a Phillips Medisize manufacturing site in Queretaro, Mexico.
Pre-clinical study to explore use of MODD1 pump as a delivery system for FDA-approved, short acting peptides, as a personalized alternative for people who discontinue long-acting GLP-1 formulations
